Roche: stock down as phase III trial fails

(CercleFinance.com) - Roche shares opened down sharply on Wednesday in Zurich (currently down 5.
5%) after the Swiss pharmaceutical company announced the failure of a clinical trial involving a new treatment for bronchial cancer.

This morning the Basel-based company said that the phase III "Skyscraper-01" study combining its experimental drug tiragolumab with its blockbuster immunotherapy Tecentriq had failed to meet one of its key endpoints, namely an improvement in progression-free survival.

However, the study will continue until data are available on overall survival, another primary endpoint for which the group has so far been unable to draw conclusions.

The trial involved patients with non-small cell lung cancer whose tumours express the PD-L1 molecule, at a metastatic stage.



Copyright (c) 2022 CercleFinance.com. All rights reserved.